Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

  title={Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults},
  author={Sharon B. Wigal},
  journal={CNS Drugs},
  • S. Wigal
  • Published 1 November 2009
  • Psychology, Medicine
  • CNS Drugs
There have been major advances in the treatment and understanding of attention-deficit hyperactivity disorder (ADHD) in the last decade. Among these are the availability of newer stimulant formulations, an appreciation of the combined effects of medication and behavioural therapies, and a better understanding of the neurobiology of the disorder in children (aged 6–12 years), adolescents and adults. This article focuses on the evaluation of the efficacy and safety profiles of medications used… 

A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.

  • L. BriarsTimothy J. Todd
  • Psychology, Medicine
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2016
This review focuses on the clinical use of psychostimulant medication in children and adolescents and the pharmacodynamic and pharmacokinetic differences between the newest long-acting formulations as well as commonly encountered adverse drug reactions.

Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies

Important aspects of evaluation and assessment are reviewed and first-line pharmacological treatments are discussed and as well as when to consider using alternative pharmacological agents are discussed.

Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review

Results from this review suggest that ATX is effective in the treatment of some youth and adults with ADHD and comorbid disorders, and may be a treatment option in these patients.

Toward a New Understanding of Attention-Deficit Hyperactivity Disorder

An overview of this topic describes the important direct and indirect role of effective ADHD therapy in managing both primary and secondary disorders, as well as the critical role of appropriate adjunctive therapies aimed at comorbid conditions.

The Effectiveness of Medicinal and Non-medicinal Treatments of Attention-Deficit/Hyperactivity Disorder

The effectiveness of multiple treatment methods commonly used for this disorder as well as issues concerning the effects and over-prescription of stimulant medications has become more prominent in recent years and should be further discussed.

Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults

Clinical guidelines recommend stimulants and the nonstimulant atomoxetine as first-line treatments, followed by antidepressants, and the combination of an antidepressant and stimulants has been shown to be safe and effective.

A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): Rationale and design

The ACTION study is the first controlled trial to investigate the efficacy of atomoxetine using objective cognitive and emotional function markers, and whether these objective measures predict outcomes with atomxetine in ADHD with and without comorbid anxiety.

The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder

Although systematic trials on the use of stimulants and ATX in ADHD-BD comorbidity in adulthood are necessary, both treatments should be considered possible options to be carefully evaluated once the patient has been stabilized.

Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder

Evidence has shown that stimulants, along with the non-stimulants atomoxetine and extended-release guanfacine, are continuously effective for 24-month treatment periods with few and tolerable adverse effects.



Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.

The available literature indicates the important role of psychopharmacological agents in the reduction of the core symptoms of ADHD and associated impairments.

Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches

This review focuses on etiology, assessment and treatment of ADHD, in particular alternative treatment approaches with various nonstimulant agents, especially atomoxetine.

Attention-deficit hyperactivity disorder

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

  • R. Weisler
  • Medicine, Psychology
    Expert opinion on pharmacotherapy
  • 2007
A number of long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD) have recently been developed and approved for use in the US and appear to have a lower risk of abuse and diversion and may be associated with significant improvements in medication adherence.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD, however, this trial showed no evidence for ATX of efficacy in treating MDD.

Non–stimulant medications in the treatment of ADHD

A large and still increasing body of data supports the usefulness of atomoxetine, a once daily dosing, and new selective noradrenalin reuptake inhibitor, with few side effects.

Effect of stimulants on height and weight: a review of the literature.

Treatment with stimulants in childhood modestly reduced expected height and weight and more work is needed to clarify the effects of continuous treatment from childhood to adulthood.

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.

Clonidine may be an effective second-tier treatment for symptoms of ADHD, but it has an effect size less than that of stimulants.